ArticleIranian journal of basic medical sciences2014
Numerical status of CD4(+)CD25(+)FoxP3(+) and CD8(+)CD28(-) regulatory T cells in multiple sclerosis.
Article in Iranian journal of basic medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto's Thyroiditis.Frontiers in immunology · 2018Trial
- Bioactive Phytochemicals in Experimental Models of Multiple Sclerosis: Mechanisms, Efficacy, and Translational Potential.Nutrients · 2026Review
- T cell-mediated immunodysregulation in multiple sclerosis: from pathogenic subsets to therapeutic advances.Frontiers in immunology · 2026Review
- MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis.Journal of neuroinflammation · 2024Article
- Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17/Treg balance.Journal of translational medicine · 2024Review
- Improving regulatory T cell production through mechanosensing.Journal of biomedical materials research. Part A · 2024Article
- Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells.Biomedicines · 2024Article
- Article
- Mitochondrial-regulated Tregs: potential therapeutic targets for autoimmune diseases of the central nervous system.Frontiers in immunology · 2023Review
- Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers.Human vaccines & immunotherapeutics · 2022Review
- Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis.Regenerative therapy · 2022Review
- Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.Molecular biology reports · 2022Review
- Improving the Efficacy of Regulatory T Cell Therapy.Clinical reviews in allergy & immunology · 2022Review
- Regulatory Cells in Multiple Sclerosis: From Blood to Brain.Biomedicines · 2022Review
- Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration.Current neuropharmacology · 2022Review
- Multiple sclerosis patients have reduced resting and increased activated CD4Scientific reports · 2021Article
- Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease.Frontiers in immunology · 2021Review
- A new clustering method identifies multiple sclerosis-specific T-cell receptors.Annals of clinical and translational neurology · 2021Article
- Increased frequency of CD4Gene reports · 2019Article
- Immunomodulatory Effect of Pregnancy on Leukocyte Populations in Patients With Multiple Sclerosis: A Comparison of Peripheral Blood and Decidual Placental Tissue.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRegulatory T cells, including CD4+CD25+Fox3+ and CD8+CD28- cells play an important role in regulating the balance between immunity and tolerance. Since multiple sclerosis is an inflammatory autoimmune disease, regulatory T cells are considered to be involved in its pathogenesis. In this study, we investigated the circulatory numbers of the two mentioned types of regulatory T cells and also their association with different clinical characteristics in 84 multiple sclerosis patients. MATERIALS AND
methods84 patients with multiple sclerosis and 75 normal individuals were studied. Demographic and clinical information of all participants were collected via questionnaire and clinical examination as well as MRI. The peripheral blood frequency of two different subgroups of regulatory T cells (CD4+ CD25+Foxp3+ and CD8+CD28- cells) were analyzed by flow cytometry using anti-human antibodies conjugated with CD4-FITC / CD25-PE/Foxp3-PE-Cy5, CD3-PE/CD8a-PE-Cy5/CD28-FITC.
resultsThe frequency of CD4+CD25+Foxp3+ cells in multiple sclerosis patients was significantly less than that in healthy controls (P=0.006) and in mild forms less than that in sever forms (P=0.003). There was not any correlation between the frequency of regulatory T cells and different clinical variables.
conclusionOur results showed that the number of CD4+CD25+Foxp3+ cells decreases significantly in multiple sclerosis patients, which probably shows the regulatory role of these cells in multiple sclerosis.
Indexed as
Identifiers
24904717PMC4046232W1560784230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.